Deferoxamine: all 35 studies that test it
Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Synergistic Minimally Invasive Surgery and Deferoxamine in ICHNot yet recruitingNCT07162363Phase 2/3
- Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingNCT07023666Phase 2
- The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBALRecruitingNCT06763055Phase 3
- A Study of Deferoxamine (DFO) in People With Leptomeningeal MetastasisRecruitingNCT05184816Phase 1
- Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)RecruitingNCT04566991Phase 2
- Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot UlcersNot yet recruitingNCT03137966Phase 2
- Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney InjuryCompletedNCT04633889Phase 2Results posted
- Intracerebral Hemorrhage Deferoxamine Trial - iDEF TtrialCompletedNCT02175225Phase 2Results posted
- High-Dose Deferoxamine in Intracerebral HemorrhageTerminatedNCT01662895Phase 2Results posted
- Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadTerminatedNCT01459718Phase 2Results posted
- Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedNCT01254227Phase 2Results posted
- Deferoxamine for Iron Overload Before Allogeneic Stem Cell TransplantationTerminatedNCT00658411Not applicableResults posted
- Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsCompletedNCT00110617Phase 2Results posted
- Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNCT06468423Not applicable
- Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast CancerTerminatedNCT05300958Phase 2
- Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 InfectionStatus unknownNCT04389801Phase 4
- Application of Desferal to Treat COVID-19Status unknownNCT04333550Phase 1/2
- Deferoxamine for Sickle Cell Chronic Leg Ulcer TreatmentWithdrawnNCT04058197Phase 1/2
- Desferal Administration to Improve the Impaired Reaction to Hypoxia in DiabetesStatus unknownNCT03085771Phase 2
- Deferoxamine in Aneurysmal Subarachnoid Hemorrhage TrialStatus unknownNCT02875262Phase 1/2
- Deferoxamine and Xingnaojing Injection Treatment in Intracerebral HemorrhageStatus unknownNCT02367248Phase 1/2
- Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid HemorrhageTerminatedNCT02216513Early Phase 1
- Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)Status unknownNCT01996683Not applicable
- Modulation of Cerebral Blood Flow Using Iron ChelatorsCompletedNCT01365104Early Phase 1
- N-acetylcysteine Plus Deferoxamine for Patients With HypotensionCompletedNCT00870883Phase 2
- Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia MajorCompletedNCT00800761Phase 4
- Thrombolysis and Deferoxamine in Middle Cerebral Artery OcclusionCompletedNCT00777140Phase 2
- Iron Balance Study of Deferasirox, Deferoxamine and the Combination of BothStatus unknownNCT00738413Phase 1/2
- Efficacy Study of the Use of Sequential DFP-DFO Versus DFPCompletedNCT00733811Phase 4
- Dose Finding and Safety Study of Deferoxamine in Patients With Brain HemorrhageCompletedNCT00598572Phase 1
- Study With Deferiprone and/or Desferrioxamine in Iron Overloaded PatientsCompletedNCT00350662Phase 3
- Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent PatientsCompletedNCT00349453Phase 2
- Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 4
- Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00067080Phase 2
- Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional HemochromatosisCompletedNCT00000595Phase 2